Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals
Sarah E. Smith-Jeffcoat, Jessica E Biddle, H. Keipp Talbot, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1175-1184
Open Access | Times Cited: 22
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 21
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 8
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong
David Tak Wai Lui, Matthew S. H. Chung, Eric H. Y. Lau, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314393-e2314393
Open Access | Times Cited: 17
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform
Bang Zheng, John Tazare, Linda Nab, et al.
The Lancet Regional Health - Europe (2023) Vol. 34, pp. 100741-100741
Open Access | Times Cited: 16
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
Zhitao Yang, Yu Xu, Ruizhi Zheng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241765-e241765
Open Access | Times Cited: 6
Post-acute sequelae of hospitalised COVID-19 re-infection compared with hospitalised first-time infection: a population-based retrospective cohort study in Hong Kong
Vincent Ka Chun Yan, Yin Zhang, Deliang Yang, et al.
BMJ Public Health (2025) Vol. 3, Iss. 1, pp. e000833-e000833
Open Access
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
Bahman Amani, Arash Akbarzadeh, Behnam Amani, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Open Access | Times Cited: 14
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023
Calvin Sjaarda, Lynette Lau, Jared T. Simpson, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2324963-e2324963
Open Access | Times Cited: 12
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Carlos King Ho Wong, Jonathan J. Lau, Ivan Chi Ho Au, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
Gordon Chun‐Kau Chan, Grace Lui, Ngai Sze Wong, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 10, pp. 1406-1412
Open Access | Times Cited: 11
Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: a retrospective cohort study
Yingsha Chen, Yushi Lin, Huidan Lu, et al.
Diagnostic Microbiology and Infectious Disease (2024) Vol. 109, Iss. 4, pp. 116353-116353
Open Access | Times Cited: 3
Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action
A. Chiarelli, Hana M. Dobrovolny
Interdisciplinary Sciences Computational Life Sciences (2024) Vol. 16, Iss. 4, pp. 844-853
Closed Access | Times Cited: 3
SARS-CoV-2 rebound with and without antivirals
Nicola Petrosillo
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 637-639
Open Access | Times Cited: 8
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation
Carlos King Ho Wong, Kristy T. K. Lau, Matthew S. H. Chung, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 112-116
Closed Access | Times Cited: 8
Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies
Tzong‐Yow Wu, Wan-Ting Tsai, Kai-Hsiang Chen, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 3, pp. 403-413
Open Access | Times Cited: 2
The glycosaminoglycan-binding chemokine fragment CXCL9(74–103) reduces inflammation and tissue damage in mouse models of coronavirus infection
Vívian Louise Soares de Oliveira, Celso Martins Queiroz‐Junior, Delphine Hoorelbeke, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications
Keiji Nakamura, Takeyuki Goto, Kenichiro Shiraishi, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 6
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection
Carolin M. Lieber, Hae-Ji Kang, Elizabeth B. Sobolik, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top